• भारत सरकार के विज्ञान एवम प्रौदयोगिकी मंत्रालय के जैव प्रौदयोगिकी विभाग की स्वायत्त संस्थान
  • Home
  • Faculty Profile


  1. Research Articles = 19  and  Book Chapters = 5.
    1. Chauhan P, Datta I, Dhiman A, Shankar U, Kumar A, Vashist Atul*, Sharma TK*, Tyagi JS* (2022) (Corresponding Author) A DNA aptamer targets Mycobacterium tuberculosis DevR/DosR response regulator function by inhibiting its dimerization and DNA binding activity. (Manuscript under Review).
    2. Malhotra V*, Okon BP, Satsangi AT, Das S, Waturuocha UW, Vashist Atul, Clark-Curtiss JE and Saini DK. (2022) Mycobacterium tuberculosis PknK substrate profiling reveals essential transcription  terminator protein Rho, and Two-component response regulators PrrA and MtrA as novel targets  for phosphorylation. Microbiol Spectr. 2022 Apr 11:e0135421.I.F. 7.17.
    3. Hussain MS, Vashist Atul*, Kumar M, Taneja NK, Gautam US, Dwivedi S, Tyagi JS and Gupta RK*. (2022) Anti-mycobacterial activity of heat and pH stable high molecular weight protein(s) expressed by a serendipitous bacterial contaminant. Microbial Cell Factories. 2022; 21(15):13 (*Corresponding Author). I.F 5.14.
    4. Vashist A, Atluri VS, Raymond AD, Kaushik A, Parira T, Huang Z, Durygin A, Tomitaka A, Nikkhah-Moshaie R, Vashist Atul, Agudelo M. (2020) Development of multifunctional biopolymeric auto-fluorescent micro-and nanogels as a platform for biomedical applications. Frontiers in Bioengineering and Biotechnology. 2020; 8:315. I F:  5.89
    5. Vashist A, Ghosal A, Vashist Atul, Kaushik A, Gupta YK, Nair M, Ahmad S.(2019). Impact of Nanoclay on the pH-Responsiveness and Biodegradable Behavior of Biopolymer-Based Nanocomposite Hydrogels.Gels. 2019 Oct 16;5(4). pii: E44. doi: 10.3390/gels5040044. IF: 4.7
    6. Sharma S, Kumari P, Vashist Atul, Kumar Chanchal, Nandi M, and Tyagi J.S. (2018). Cognate sensor kinase-independent activation of Mycobacterium tuberculosis response regulator DevR (DosR) by acetyl phosphate: Implications in anti-mycobacterial drug design. Molecular Microbiology. IF:  3.5.
    7. Vashist Atul#, Malhotra V#, Sharma G, Tyagi JS, Clark-Curtiss JE. (2018) Interplay of PhoP and DevR response regulators defines expression of the dormancy regulon in virulent Mycobacterium tuberculosis. J Biol Chem. 2018 Sep 4. doi: 10.1074/jbc.RA118.004331. IF:  5.16.
    8. Vashist A, Kaushik A, Vashist Atul, Bala J, Nikkhah-Moshaie R, Sagar V, Nair M. (2018) Nanogels as potential drug nanocarriers for CNS drug delivery. Drug Discov Today. 2018 Jul;23(7):1436-1443. doi: 10.1016/j.drudis.2018.05.018. Epub 2018 May 20.IF:  7.85.
    9. Vashist A, Kaushik A, Vashist Atul, Sagar V, Ghosal A, Gupta YK, Ahmad S, Nair M. Advances in Carbon Nanotubes-Hydrogel Hybrids in Nanomedicine for Therapeutics. (2018) Adv Healthc Mater. 2018 May;7(9):e1701213. doi: 10.1002/adhm.201701213. Epub 2018 Feb 1. IF:  9.93.
    10. Sikri K, Duggal P, Kumar C, Batra SD, Vashist Atul, Bhaskar A, Tripathi K, Sethi T, Singh A, Tyagi JS. (2018) Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs. Redox Biol. 2018 May;15:452-466. doi: 10.1016/j.redox.2017.12.020. Epub 2018 Jan 3.IF: 11.79.
    11. Vashist A, Kaushik A, Alexis K, Jayant R.D, Sagar V, Vashist Atul, Nair M. (2017) Bioresponsive Injectable Hydrogels for On-demand Drug Release and Tissue Engineering. Curr Pharm Des. 2017 May 16. IF: 2.20.
    12. Vashist Atul, Prithvi Raj D, Gupta UD, Bhat R, Tyagi J.S. (2016) The α10 helix of DevR, the Mycobacterium tuberculosis dormancy response regulator, regulates its DNA binding and activity. FEBS Journal, 2016 Jan 22. doi: 10.1111/febs.13664. IF: 5.54.
    13. Vashist Atul, Prithvi Raj D, Gupta UD, Bhat R, Tyagi JS. (2016). Importance of the α10 helix for DevR activation: A road map for screening inhibitors against DevR-mediated dormancy of Mycobacterium tuberculosis. Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S92-S93. doi: 10.1016/j.ijmyco.2016.09.030. Epub 2016 Nov 11. IF: 1.2.
    14. Thakral P, Singla S, Vashist Atul, Yadav M.P, Gupta S.K, Tyagi J.S, Sharma A, Bal C.S, Snehlata, Malhotra A, (2016) Preliminary experience with Yttrium -90 -labelled Rituximab (chimeric anti CD-20 antibody) in patients with relapsed and refractory B cell Non-Hodgkins Lymphoma. Curr Radiopharm. 2016;9(2):160-8. IF:0.84.
    15. Vashist A, Kaushik A, Vashist Atul, Jayant RD, Tomitaka A, Ahmad S, Gupta YK, Nair M,. (2016) Recent trends on hydrogel based drug delivery systems for infectious diseases. Biomater Sci. Oct 18;4(11):1535-1553. IF: 6.83.
    16. Gautam U.S, Sikri K, Vashist Atul, Singh V, Tyagi J.S. (2014) Essentiality of DevR/DosR Interaction with SigA for the Dormancy Survival Program in Mycobacterium tuberculosis. Journal of Bacteriology 196 (4) 790-799. IF: 3.0.
    17. Thakral P, Singla S, Yadav MP, Vashist Atul, Sharma A, Gupta S.K, Bal C.S, Snehlata, Malhotra A. (2014) An approach for conjugation of 177Lu- DOTA-SCN-Rituximab (BioSim) and its evaluation for radioimmunotherapy of relapsed and refractory B-cell Non Hodgkins Lymphoma patients. Indian J Med Res.;139(4):544-54. IF: 1.5.
    18. Vashist A, Vashist Atul, Gupta Y.K, Ahmad S, (2014) Recent advances in hydrogel based drug delivery systems for the human body. Journal of Materials Chemistry B 2 (2), 147-166. IF: 6.33.
    19. Majumdar S.D, Vashist Atul, Dhingra S, Gupta R, Singh A, Challu V.K, Ramanathan V.D., Kumar P, Tyagi J.S. (2012) Appropriate DevR (DosR)-mediated signaling determines transcriptional response, hypoxic viability and virulence of Mycobacterium tuberculosis. PLoS One 4: e35847. IF: 2.7.
    20. Majumdar S.D, Sharma D, Vashist Atul, Kaur K, Taneja N.K, Chauhan S, Challu V.K, Ramanathan V.D, Balasangameshwara V, Kumar P, and Tyagi J.S. (2010). Co-expression of DevR and DevR(N)-Aph proteins is associated with hypoxic adaptation defect and virulence attenuation of Mycobacterium tuberculosis. PLoS One 5: e9448. IF: 2.7.
    21. Vashist Atul, Sikri K, Lavania S, Gupta U D, Tyagi J.S. Perturbation of signaling by isolated receiver domain of DevR Response Regulator knocks down its gene function in Mycobacterium tuberculosis. (Manuscript under preparation).

1.       Arti Vashist, Rabia Kauser, Ajeet Kaushik, Atul Vashist, Rahul Dev Jayant, Sharif Ahmad, Madhavan Nair. Polymeric Nanocomposite Hydrogels for Emerging Biomaterials. In Biopolymers and Nanocomposites for Biomedical and Pharmaceutical Applications ISBN: 978-1-53610-635-0 Editors : E. Sharmin and F. Zafar ©2017 Nova Science Publisher, Inc.

2.      Chopra V, Chauhan G, Kumar R, Kulkarni MM, Vashist A* (Corresponding Author). Nanogels in the Diagnosis and Treatment of Tuberculosis. In Nanogels for Biomedical Applications 2017 Nov 14 (pp. 53-76). RSC Publications.

3.      Kumar R, Vashist A, Mathur A, Sarangi S.C, Padhy B.M, and Gupta Y.K. (2017) Nanogels: Stimuli-responsive Drug Delivery Carriers. In Nanogels for Biomedical Applications. pp 161-180. RSC Publications.

4.      Vashist A, Kaushik A, Ghosal A, Nikkhah-Moshaie R, Vashist A, Jayant RD, Nair M (2017). Journey of hydrogels to nanogels: a decade after. In Nanogels for Biomedical Applications 2017 Nov 14 (pp. 1-8). RSC Publications.

5.      Vashist A, Kaushik A, Jayant R.D, Vashist A, Ghosal A, and Nair M. (2017) Hydrogels: Stimuli Responsive to on-Demand Drug Delivery Systems. In Advances in Personalized Nanotherapeutics, Springer. pp 117-130.

  1. Young Scientist, DST, Start-Up Research Grant (~ Rs. 35.55 lakhs)     Status: Completed          Duration:    12/2015 – 08/2018

     Title:  Role of Vitamin C-mediated dormancy in improving the efficacy of Bedaquiline against Mycobacterium tuberculosis.

     Host Institutuion: Department of Biotechnology, All India Institute of Medical Sciences, New Delhi-110029.

  • Awarded with Marie Sklodowska-Curie RESPIRE3 fellowship 2018 (2nd Call) by ERS/EU.
  • Selected as Brand Ambassador for Bentham Sciences in June 2018.
  • Global Health Award by Bill & Melinda Gates Foundation, USA.
  • International Travel grant from DST, Govt. of India, for Oral presentation at 4th SA TB Conference, June 10 – 13, 2014, ICC, Durban, South Africa.
  • International Travel grant from ICMR, Govt. of India, for Poster presentation at Gordan Research Conference: Tuberculosis Drug Development, July, 2011, Lucca (Barga) Italy.
  • Elected as Member in Executive Committee for Society for Young Scientist, AIIMS, New Delhi. (2007-2008).                                                                    
  • Membership of Professional Bodies
  1. Member of Stop TB Partnership Working Group on New Drugs (WGND), New York, USA.
  2. Member of Royal Society of Chemistry (MRSC). (Membership No. 639189)
  3. Member of Asian African Society of Mycobacteriology (AASM).
  4. Life Member of Indian Society of Chemists and Biologists. (Membership Id: LF/1125/2021).
  5. Life Member of Indian Society of Cell Biology. (Membership No. 2021001).
  6. Life Member of Society of Biological Chemists of India. (Membership No.: 4260).
  7. Editorial Board Member in Biomedical and Biotechnology Research Journal (BBRJ).
  8. Editorial Board Member in Journal of Biomedical and Therapeutic Sciences - International journal for Biomedical Research and Clinical studies advances (ISSN: 2394-2274).
  9. Guest Editor in Special Issue "Emerging Platforms in Nanotechnology for Diagnosis and Treatment of Respiratory and Infectious Diseases" Pharmaceuticals Journal by MDPI.
  10. Editorial Board Member in PLOS Global Public Health Journal.

Poster Presentations

1.“Development and characterization of G-Quadruplex-forming DNA aptamers targeting DevR/DosR response regulator of Mycobacterium tuberculosis” in EMBO Workshop on Mycobacterial heterogeneity and host tissue tropism from 11 – 15 February 2020 at ICGEB, New Delhi, India.

2.“A rapid molecular assay to screen inhibitors of DevR/DosR mediated dormancy programme of Mycobacterium tuberculosis” in UK-India Workshop on Tackling the Emergence of Antimicrobial Resistance: Increasing Awareness and Facilitating Research Networks, November 7-10, 2016 at CSIR-IMTECH, Chandigarh, India.

3. “The C-terminal α10 helix is essential for phosphorylation-mediated activation of DevR/DosR response regulator in Mycobacterium tuberculosis” in Proc. of MCB 75: From Molecules to Organisms Conference December 11-14, 2015, at Indian Institute of Science, Bangalore, India.

4. “Inhibitory activity of DevR-Aph fusion protein co-expressed with DevR (DosR) in M. tuberculosis”, in Proc. of Gordan Research Conference: Tuberculosis Drug Development, July 3 - 8, 2011, Lucca (Barga) Italy.

5.“Defective Hypoxic Adaptation and Virulence Attenuation of Mycobacterium tuberculosis is Associated with Co-Expression of DevR and DevRN-Aph Proteins”, in Proc. of International Symposium on Emerging Trends in Tuberculosis Research, December 16-17, 2010, International Centre for Genetic Engineering and Biotechnology, New Delhi.

Oral Presentations/Talks

1. Perturbation of signaling by isolated receiver domain of DevR/DosR Response Regulator knocks down its gene function in Mycobacterium tuberculosis (2019). Challenges of TB: UK-India Newton-Bhabha Fund RSC Researcher Links Workshop from 16-19 Dec, 2019 at IISER, Pune, India

2. Development of molecular strategies to direct the switches between dormant and active states of Mycobacterium tuberculosis: Implications for efficacy of anti-tubercular drugs. (2017). UK-India Newton-Bhabha Fund RSC Researcher Links Workshop on working at the chemistry-microbiology interface to develop new antibiotics for tackling antimicrobial resistance and resistant TB from 14-18 December, 2017 at Rajiv Gandhi Institute of Chest Diseases (RGICD), Bengaluru, India.

3. Importance of the α10 helix for DevR activation: A road map for screening inhibitors against DevR-mediated dormancy of Mycobacterium tuberculosis (2016) in 2nd Congress of Asian African Society of Mycobacteriology  from 25-28 Feb, 2017 at Isafahan, Iran.

4. “A Critical Concentration of DevR/DosR Triggers the Hypoxia Associated Dormancy Programme and Virulence of Mycobacterium tuberculosis” in Proc. Of 4th SA TB Conference, June 10 – 13, 2014, ICC, Durban, South Africa.

  • 01292876498